CAMBRIDGE, Mass., June 1, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a webcast and conference call this morning to highlight key aspects of the company's recent clinical progress and review several abstracts accepted by the American Society of Clinical Oncology (ASCO) for presentation during the 47th Annual Meeting being held from June 3 through June 7 in Chicago, Ill. Data to be presented at the ASCO meeting include results from clinical trials of IPI-926, Infinity's oral molecule which targets the Hedgehog pathway by inhibiting Smoothened, and retaspimycin hydrochloride (HCl) (also known as IPI-504), the company's novel heat shock protein (Hsp90) inhibitor.
